Humana Inc (HUM) Shares Sold by University of Notre Dame DU Lac

University of Notre Dame DU Lac decreased its position in Humana Inc (NYSE:HUM) by 5.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,151 shares of the insurance provider’s stock after selling 532 shares during the quarter. University of Notre Dame DU Lac’s holdings in Humana were worth $2,473,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HUM. Janus Henderson Group PLC raised its position in Humana by 7,848.8% in the second quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock valued at $377,192,000 after purchasing an additional 1,547,866 shares during the period. FMR LLC raised its position in Humana by 29.3% in the second quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock valued at $1,571,264,000 after purchasing an additional 1,479,210 shares during the period. Koch Industries Inc. purchased a new stake in Humana in the second quarter valued at approximately $404,000. TIAA CREF Investment Management LLC raised its position in Humana by 39.7% in the second quarter. TIAA CREF Investment Management LLC now owns 1,358,617 shares of the insurance provider’s stock valued at $326,910,000 after purchasing an additional 386,162 shares during the period. Finally, Ameriprise Financial Inc. raised its position in Humana by 39.8% in the second quarter. Ameriprise Financial Inc. now owns 1,322,413 shares of the insurance provider’s stock valued at $318,216,000 after purchasing an additional 376,177 shares during the period. 94.19% of the stock is currently owned by institutional investors.

Shares of Humana Inc (NYSE:HUM) traded up $1.06 during mid-day trading on Wednesday, hitting $253.34. 927,700 shares of the company were exchanged, compared to its average volume of 1,384,502. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $36,040.74, a P/E ratio of 21.53, a P/E/G ratio of 1.73 and a beta of 0.88. Humana Inc has a 12-month low of $186.25 and a 12-month high of $264.56.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.12. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. The company’s revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.18 earnings per share. equities analysts expect that Humana Inc will post 11.63 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, December 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.63%. Humana’s payout ratio is currently 12.59%.

A number of research firms have recently weighed in on HUM. Credit Suisse Group cut their price objective on Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. BMO Capital Markets upped their price objective on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, November 10th. Morgan Stanley cut their price objective on Humana from $276.00 to $270.00 and set an “overweight” rating on the stock in a research report on Thursday, November 9th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $242.00 price objective (down previously from $245.00) on shares of Humana in a research report on Thursday, November 9th. Finally, Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Twelve research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Humana presently has an average rating of “Hold” and a consensus price target of $255.45.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/12/06/humana-inc-hum-shares-sold-by-university-of-notre-dame-du-lac.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply